Q3 2022 Calliditas Therapeutics AB Earnings Call Transcript
Welcome to Calliditas Therapeutics Quarter 3 Presentation 2022.
(Operator Instructions)
I will now hand over the word to CEO, Renee Aguiar-Lucander, please begin the meeting.
()-
Thank you very much, and welcome, everybody, to the Q3 report. With me on today's call, I have Fredrik Johansson, our Chief Financial Officer; Richard Philipson, Chief Medical Officer; and Mr. Andrew Udell, President of North America. So if you go to Page 2, please. I'd like to draw your attention to the disclaimer page related to forward-looking statements and refer you to the company's reports and other filings including those filings which contain risk factors and other relevant information.
So if we turn to Page 3, please. So some of the Q3 highlights. So in this quarter, Calliditas has achieved another major milestone as we received formal conditional approval of Kinpeygo in Europe. Subsequent to achieving this, we immediately started the transfer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
